Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Titouan Cazaubiel, Laure Buisson, Sabrina Maheo, Laura Do Souto Ferreira, Romain Lannes, PhD, Aurore Perrot, Cyrille Hulin, MD, Hervé Avet-Loiseau, MD PhD, Jill Corre, PharmD, PhD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-139340

Published: 2020

Journal Articles

Timing the Initiation of Multiple Myeloma

Blood (2019) 134 (Supplement_1): 573.

https://doi.org/10.1182/blood-2019-124357

Published: 2019

Journal Articles

Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Michael A Lopez, Sanika Derebail, Kenneth C. Anderson, MD, Herve Avet-Loiseau, MD PhD, Giovanni Parmigiani, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 361.

https://doi.org/10.1182/blood-2019-129114

Published: 2019

Journal Articles

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Maria Ortiz, Fadi Towfic, PhD, Erin Flynt, Nicholas Stong, PhD, Sneh Lata, PhD, Dharanya Sampath, Dan Rozelle, PhD, Matthew Trotter, PhD, Jill Corre, PharmD, PhD, Hervé Avet-Loiseau, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 366.

https://doi.org/10.1182/blood-2019-128907

Published: 2019

Journal Articles

Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Murielle Roussel, MD, Benjamin Hebraud, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Thierry Facon, MD, Eileen Boyle, MD PhD, Cyrille Touzeau, MD PhD, Brigitte Pegourie, MD, Aurore Perrot, MD PhD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Philippe Moreau, MD, Herve Avet-Loiseau, MD PhD, Laure Devlamynck, Valerie Lauwers-Cances, MD, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3159.

https://doi.org/10.1182/blood-2019-123184

Published: 2019

Journal Articles

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Tessa Han, Stephane Minvielle, PhD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Florence Magrangeas, PhD, Paul G. Richardson, MD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Hervé Avet-Loiseau, MD PhD, Giovanni Parmigiani, PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4348.

https://doi.org/10.1182/blood-2019-130343

Published: 2019

Journal Articles

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Blood (2019) 134 (Supplement_1): 4370.

https://doi.org/10.1182/blood-2019-127362

Published: 2019

Journal Articles

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Raphael Szalat, Jill Corre, PharmD, PhD, Niccolo Bolli, MD PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3089.

https://doi.org/10.1182/blood-2019-128570

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

Journal Articles

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Blood (2019) 134 (Supplement_1): 1784.

https://doi.org/10.1182/blood-2019-131257

Published: 2019

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

PDZ Binding Kinase (PBK) - a Novel Gene Driving Genomic Evolution in Multiple Myeloma

Subodh Kumar, PhD, Leutz Buon, Srikanth Talluri, PhD, Jialan Shi, MD PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Masood A. Shammas, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 4474.

https://doi.org/10.1182/blood-2018-99-119186

Published: 2018

Journal Articles

Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control

Mariateresa Fulciniti, PhD, Michael A Lopez, Anil Aktas Samur, PhD, Eugenio Morelli, MD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 4500.

https://doi.org/10.1182/blood-2018-99-118845

Published: 2018

Journal Articles

Critical Role for Apobec and Its Interacting Partners in Mediating Mutations and Cell Growth in Multiple Myeloma (MM)

Srikanth Talluri, PhD, Mehmet Kemal Samur, PhD, Jialan Shi, MD PhD, Rao Prabhala, PhD, Hervé Avet-Loiseau, MD PhD, Masood A. Shammas, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 4462.

https://doi.org/10.1182/blood-2018-99-118441

Published: 2018

Journal Articles

Light Chain Escape in Multiple Myeloma

Thomas Dejoie, MD, Guillemette Fouquet, Cyrille Hulin, Murielle Roussel, Benjamin Hebraud, Lionel Karlin, MD, Brigitte Kolb, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Mourad Tiab, MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, Gérard Lepeu, MD, Marie Lorraine Chretien, MD, Denis Caillot, Jean Fontan, MD, Philippe Rodon, MD, Anna Schmitt, Laurent Voillat, MD, Sophie Cereja, MD, Brigitte Pegourie, MD, Frederique Kuhnowski, MD, Sophie Rigaudeau, MD, Olivier Decaux, MD, Catherine Humbrecht-Kraut, MD, Jamilé Frayfer, MD, Laurent Garderet, Damien Roos-Weil, MD, Jean Claude Eisenmann, MD, Veronique Dorvaux, MD, Eric G. Voog, MD, Claire Mathiot, MD, Jean-Paul Fermand, MD, Thierry Facon, Hervé Avet-Loiseau, MD PhD, Jean Luc Harousseau, MD, Philippe Moreau, Michel Attal, MD PhD, Xavier Leleu, MD PhD

Blood (2018) 132 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2018-99-112396

Published: 2018

Journal Articles

Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

Blood (2018) 132 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2018-99-111934

Published: 2018

Journal Articles

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Hervé Avet-Loiseau, MD PhD, Jesus F San-Miguel, MD PhD, Tineke Casneuf, PhD, Shinsuke Iida, MD PhD, Sagar Lonial, MD, Saad Z. Usmani, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Philippe Moreau, Torben Plesner, MD DSc, Katja Weisel, MD, Jon Ukropec, PhD, Linda Okonkwo, Sonali Trivedi, Christopher Joseph Velas, BS, Xiang Qin, Ming Qi, MD PhD, Christopher Chiu, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2018-99-113177

Published: 2018

Journal Articles

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Hervé Avet-Loiseau, MD PhD, Jianming He, PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Sourish Saha, Christopher Chiu, PhD, Sarah Cote, Annette Lam

Blood (2018) 132 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2018-99-113571

Published: 2018

Journal Articles

Pomalidomide 3rd Line Versus 4 th Line for RRMM

Blood (2018) 132 (Supplement 1): 5633.

https://doi.org/10.1182/blood-2018-99-115449

Published: 2018

NARROW

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Timing the Initiation of Multiple Myeloma

Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

PDZ Binding Kinase (PBK) - a Novel Gene Driving Genomic Evolution in Multiple Myeloma

Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control

Critical Role for Apobec and Its Interacting Partners in Mediating Mutations and Cell Growth in Multiple Myeloma (MM)

Light Chain Escape in Multiple Myeloma

Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Pomalidomide 3rd Line Versus 4 th Line for RRMM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only